Tuesday, September 29, 2026

16:00 - 16:45

AUDITORIUM MARGARITA SALAS

---

Overview

Sponsor: AseBio

---

Details

Artificial intelligence is reshaping every stage of the pharmaceutical innovation pathway, from the identification of novel therapeutic targets to clinical development, regulatory decision-making and patient access. The convergence of next-generation sequencing, integrative multi-omics, advanced machine learning and emerging European health data infrastructures is creating unprecedented opportunities to accelerate the development of safer, more effective and more personalized medicines. This round table will gather leaders from government, biotechnology, the pharmaceutical industry and biomedical research to explore how AI is transforming the entire drug development continuum. The discussion will examine how next-generation sequencing and the integration of genomics, transcriptomics, proteomics, metabolomics and other complementary data sources are enabling a deeper understanding of disease biology, improving target identification and validation, and advancing biomarker discovery for precision medicine. The conversation will then address the application of AI throughout clinical development, including trial design, patient stratification, digital endpoints, real-world evidence generation and regulatory science. Particular attention will be given to the opportunities created by the European Health Data Space (EHDS), which will provide an unprecedented framework for the secure and responsible secondary use of health data to support biomedical research, innovation and evidence generation across Europe. Beyond the technological advances, the panel will discuss the governance, interoperability and trust frameworks required to translate AI into clinical and societal value. Speakers will also consider how emerging European policy initiatives, including the forthcoming European Biotech Act, can strengthen Europe's innovation ecosystem by fostering investment, enabling responsible data sharing, supporting regulatory innovation and reinforcing the continent's competitiveness in AI-enabled biotechnology. Bringing together perspectives from industry, academia and public administration, this session will offer a strategic discussion on how Europe—and Spain in particular—can leverage artificial intelligence, integrative 'omics and health data to accelerate biomedical innovation while ensuring scientific excellence, regulatory confidence and better outcomes for patients.